Latest Anagenics News

Anagenics Limited has completed a significant restructuring to simplify operations and issued 35 million shares to FOS Capital as part of this process. The company confirms its going concern status and outlines plans for organic and acquisitive growth over the next year.

Anagenics Limited has reported a net profit before tax of $138,000 for the quarter ended March 31, 2025, marking a significant turnaround following recent restructuring efforts. Despite a temporary revenue setback due to a warehousing transition, the company’s operating cash flow improved markedly.

Anagenics Limited reported a cash outflow of $424K for Q3 2025 but maintains robust liquidity with $1.48 million in available funding, supported by a mix of secured and unsecured loans.

Anagenics reports a marked reduction in operating cash outflow and expenses following a strategic restructuring, setting the stage for improved financial stability in the coming quarter.

Anagenics Limited reports a marked reduction in cash outflows and operating costs following a strategic restructuring, with full benefits expected in the latter half of FY2025. Despite divesting Face Medi, core cosmetics sales remain steady.